Search Result

Results for "

non-covalent interaction

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aldose Reductase (1) Apoptosis (2) Bacterial (4) Biochemical Assay Reagents (2) Btk (1) Calcium Channel (2) Cathepsin (1) COX (2) DNA Alkylator/Crosslinker (2) DNA Stain (1) Endogenous Metabolite (3) Environmental Pollutants (1) ERK (2) Fungal (1) Glycosidase (1) HIV (1) HSP (2) Lactate Dehydrogenase (1) LDLR (1) Parasite (2) PERK (1) Phosphatase (2) Ras (4) Reference Standards (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Infection (7) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148439

Daraxonrasib Maximum Cited Publications 10 Publications Verification RMC-6236; RAS-IN-2	Ras PERK	Cancer
Daraxonrasib (RMC-6236) is an orally active, non-covalent RAS (ON) inhibitor. Daraxonrasib disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC₅₀ values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. Daraxonrasib inhibits pERK. Daraxonrasib has anti-tumor activity against KRAS mutant tumors .

HY-P3152

Streptavidin 5 Publications Verification	Biochemical Assay Reagents	Others
Streptavidin is a ~60 kDa homotetramer. Streptavidin binds four molecules of biotin with the highest affinity. The binding affinity of biotin to streptavidin is one of the highest reported for a non-covalent interaction to date, with a K_D ~0.01 pM . Streptavidin has an immunosuppressive role . This product is a Streptavidin protein recombinantly expressed in an E. coli expression system.

HY-152857

Muvalaplin LY3473329	LDLR	Cardiovascular Disease
Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) (Lp (a)) that disrupts the initial non-covalent interaction between apo(a) and apoB100, preventing the disulphide bond and Lp(a) formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys .

HY-W015954

(2R,3R)-Butane-2,3-diol	Endogenous Metabolite Calcium Channel Bacterial	Infection Metabolic Disease
(2R,3R)-Butane-2,3-diol is a non-covalent, reversible agonist targeting lanthanum (La ³⁺)-sensitive calcium channels in bacteria (e.g., Escherichia coli) with an EC₅₀ of approximately 25 mM. (2R,3R)-Butane-2,3-diol binds to calcium channel proteins or related complexes, induces channel opening, promotes extracellular calcium influx, and triggers intracellular calcium transients, which may regulate bacterial physiological activities such as growth, metabolism, and signal transduction. (2R,3R)-Butane-2,3-diol mediates bacterial-host cell signaling interactions and affects the metabolic balance of intestinal microorganisms, and can be used to study lactose intolerance and other related diseases .

HY-W145665

Amylose	Biochemical Assay Reagents Endogenous Metabolite	Others
Amylose is not a typical small-molecule ligand with a specific traditional receptor-binding target. It is a polysaccharide. In food science and biological systems, amylose can interact with proteins and free fatty acids through non-covalent forces like hydrophobic interactions and electrostatic interactions. For example, it can form a ternary complex with them, which is related to the structure and digestion of starch. It is widely studied in the fields of food science, carbohydrate metabolism, and is also relevant in research on controlling glycemic responses, as it affects starch digestion rate .

HY-137441

Icapamespib 1 Publications Verification PU-HZ151	HSP	Neurological Disease Cancer
Icapamespib (PU-HZ151; PU-AD) is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .

HY-W012817

Methylhydroquinone	Environmental Pollutants COX	Inflammation/Immunology
Methylhydroquinone is an orally active COX inhibitor with IC₅₀s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions .

HY-P4076

MPG peptides, Pβ	HIV DNA Alkylator/Crosslinker	Infection
MPG peptides, Pβ is an amphipathic cell-penetrating peptide. MPG peptides, Pβ consists of three components: the hydrophobic fusion sequence (GALFLGFLGAAGSTMGA) of HIV glycoprotein 41, a spacer domain (WSQP), and the nuclear localization signal (KKKRKV) of the large T antigen of Simian virus 40. MPG peptides, Pβ can form stable non-covalent complexes with nucleic acids (including DNA) through electrostatic interactions and improve their intracellular delivery. MPG peptides, Pβ can be used in studies of HIV-1-related immune responses .

HY-W010538

trans-4-Methylcyclohexanamine	Parasite	Infection
trans-4-Methylcyclohexanamine is an intermediate and can be used for the development of T. cruzi enzyme inhibitor .

HY-137441A

Icapamespib hydrochloride 1 Publications Verification PU-HZ151 hydrochloride	HSP	Neurological Disease Cancer
Icapamespib (PU-HZ151; PU-AD) hydrochloride is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib hydrochloride can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib hydrochloride can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib hydrochloride can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .

HY-W582504

Chlorotris(triphenylphosphine)copper CuCl(TPP)3	DNA Stain Bacterial Fungal	Infection Cancer
Chlorotris(triphenylphosphine)copper (CuCl(TPP)₃) is a DNA-targeted metal complex. Chlorotris(triphenylphosphine)copper involves non-covalent interactions (such as groove binding mode) through the copper(I) center to affect DNA function, showing inhibitory activity against bacteria, fungi, and tumor cells. Chlorotris(triphenylphosphine)copper is promising for research of antibacterial, antitumor, and antioxidant agents .

HY-W015954R

(2R,3R)-Butane-2,3-diol (Standard)	Reference Standards Endogenous Metabolite Calcium Channel Bacterial	Infection Metabolic Disease
(2R,3R)-Butane-2,3-diol (Standard) is the analytical standard of (2R,3R)-Butane-2,3-diol (HY-W015954). This product is intended for research and analytical applications. (2R,3R)-Butane-2,3-diol is a non-covalent, reversible agonist targeting lanthanum (La ³⁺)-sensitive calcium channels in bacteria (e.g., Escherichia coli) with an EC₅₀ of approximately 25 mM. (2R,3R)-Butane-2,3-diol binds to calcium channel proteins or related complexes, induces channel opening, promotes extracellular calcium influx, and triggers intracellular calcium transients, which may regulate bacterial physiological activities such as growth, metabolism, and signal transduction. (2R,3R)-Butane-2,3-diol mediates bacterial-host cell signaling interactions and affects the metabolic balance of intestinal microorganisms, and can be used to study lactose intolerance and other related diseases .

HY-169228

WS-11	Btk	Cancer
WS-11 is a non-covalent reversible BTK inhibitor with IC₅₀s of 3.9 nM and 2.2 nM for wild type, C481S mutation BTK, respectively. WS-11 can form strong π-π interaction with PHE540 and form p-π interaction with LYS430 within the active pocket, besides the strong hydrogen bonds .

HY-162321

ZINC57632462	Ras	Cancer
ZINC57632462 (ACA-6) is a non-covalent allosteric KRAS inhibitor. ZINC57632462 disrupts nucleotide exchange and inhibits RAS-effector interaction. ZINC57632462 can be used for the research of cancer .

HY-W012817R

Methylhydroquinone (Standard)	COX Reference Standards	Others
Methylhydroquinone (Standard) is the analytical standard of Methylhydroquinone. This product is intended for research and analytical applications. Methylhydroquinone is an orally active COX inhibitor with IC50s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions[1][2].

HY-181892

LpxC-IN-17	Bacterial	Infection
LpxC-IN-17 (Compound a5) is a non-covalent LpxC inhibitor and Antibacterial agent. LpxC-IN-17 chelates catalytic zinc ions and forms extensive non-covalent interactions within the LpxC active site, thereby functionally inhibiting the enzyme. LpxC-IN-17 exhibits antibacterial activity against Gram-negative pathogens including Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. LpxC-IN-17 is applicable to research related to Gram-negative bacterial infections .

HY-181519

ALR2/α-GLY-IN-1	DNA Alkylator/Crosslinker Aldose Reductase Glycosidase	Metabolic Disease Inflammation/Immunology
ALR2/α-GLY-IN-1 is a potent dual-target inhibitor that targets aldose reductase ALR2 and α-glucosidase (IC₅₀ values are 0.72 μM and 0.82 μM, respectively; K_i values are 1.67 μM and 1.37 μM, respectively). ALR2/α-GLY-IN-1 also acts as a DNA binder, which stably interacts with calf thymus double-stranded DNA through non-covalent interactions such as groove-binding mode and water-bridged hydrogen bonds. ALR2/α-GLY-IN-1 can be used in studies related to diabetes and its complications .

HY-181420A

BBO-11818	Ras Phosphatase ERK Apoptosis	Cancer
BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC₅₀=28-120 nM). BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. BBO-11818 produces synergistic effects when combined with Cetuximab (HY-P9905), anti-PD-1 antibody or PI3Kα inhibitor. BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer .

HY-181420

(S,R,S)-BBO-11818	ERK Apoptosis Phosphatase Ras	Cancer
(S,R,S)-BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC₅₀=28-120 nM). (S,R,S)-BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. (S,R,S)-BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. (S,R,S)-BBO-11818 produces synergistic effects when combined with Cetuximab (HY-P9905), anti-PD-1 antibody or PI3Kα inhibitor. (S,R,S)-BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer .

HY-180110

Antiparasitic agent-32	Parasite Lactate Dehydrogenase	Infection
Antiparasitic agent-32 (compound M9), a Piperaquine (HY-B1896) analog, is a potent P. falciparum lactate dehydrogenase (Pf LDH)-targeting antiparasitic agent (Pf3D7 IC₅₀ = 0.40 μM). Antiparasitic agent-32 exhibits significant activity against both Pf asexual and gametocyte stages. Antiparasitic agent-32 exerts antiplasmodial activity through stable and specific noncovalent interactions at the NADH-binding site. Antiparasitic agent-32 can be used for malaria research .

HY-181676

Anti-inflammatory agent 113	Cathepsin	Inflammation/Immunology
Anti-inflammatory agent 113 (compound B5) is a Cathepsin L (CTSL) inhibitor and anti-inflammatory agent with a CTSL IC₅₀ of 5.52 μM. Anti-inflammatory agent 113 suppresses CTSL maturation, attenuates NF-κB and p38 MAPK signaling pathway activation, and binds stably in CTSL’s active site via noncovalent interactions with Asp162, Cys25, and Glu63. Anti-inflammatory agent 113 inhibits pro-inflammatory cytokine (IL-6, IL-8) production, reduces inflammatory cell lung infiltration, and alleviates lung tissue injury. Anti-inflammatory agent 113 can be used for the research of acute lung injury .

Cat. No.	Product Name

HY-LD004

DEL Covalent Library	14 million compounds
DEL technology enables the simultaneous screening of millions or billions of compounds in a single tube by covalently linking each small molecule with a unique DNA sequence. Traditional DEL screening primarily focuses on identifying non-covalent binding molecules, where interactions with the target are reversible. In contrast, DNA‑encoded covalent library is an ultra‑high‑throughput screening library developed on the basis of conventional DNA‑encoded library technology. It incorporates controllable electrophilic covalent warheads capable of forming irreversible covalent bonds with amino acid residues at the active sites of target proteins, including Cys, Lys, Ser, Tyr, and others. This covalent binding enhances binding affinity, prolongs residence time at the target site, and has the potential to overcome challenges associated with traditional non-covalent inhibitors, such as drug resistance or off-target effects. Each compound in the library contains both a binding domain and an electrophilic warhead. It first recognizes and binds to the target through non covalent interactions, and then forms a stable covalent bond with key amino acid residues to achieve irreversible inhibition. This library is specifically designed for the discovery of potent, long lasting, and highly selective covalent inhibitors, particularly for undruggable targets such as kinases, GPCRs, proteases, and mutant oncoproteins. Each molecule is uniquely labeled with a DNA barcode for molecular identification and sequencing decoding. This library is an advanced and highly diverse collection, consists of 35 independent sub-libraries with a total scaleof 14 million compounds, It incorporates over 14 experimentally validated covalent warheads capable of targeting cysteine, lysine, arginine, aspartic acid and glutamic acid. This library is constructed with diverse drug like core scaffolds and integrated controllable covalent warheads, it features structural diversity, reaction spec

DEL Covalent Library

14 million compounds

DEL technology enables the simultaneous screening of millions or billions of compounds in a single tube by covalently linking each small molecule with a unique DNA sequence. Traditional DEL screening primarily focuses on identifying non-covalent binding molecules, where interactions with the target are reversible. In contrast, DNA‑encoded covalent library is an ultra‑high‑throughput screening library developed on the basis of conventional DNA‑encoded library technology. It incorporates controllable electrophilic covalent warheads capable of forming irreversible covalent bonds with amino acid residues at the active sites of target proteins, including Cys, Lys, Ser, Tyr, and others. This covalent binding enhances binding affinity, prolongs residence time at the target site, and has the potential to overcome challenges associated with traditional non-covalent inhibitors, such as drug resistance or off-target effects.

Each compound in the library contains both a binding domain and an electrophilic warhead. It first recognizes and binds to the target through non covalent interactions, and then forms a stable covalent bond with key amino acid residues to achieve irreversible inhibition. This library is specifically designed for the discovery of potent, long lasting, and highly selective covalent inhibitors, particularly for undruggable targets such as kinases, GPCRs, proteases, and mutant oncoproteins. Each molecule is uniquely labeled with a DNA barcode for molecular identification and sequencing decoding.

This library is an advanced and highly diverse collection, consists of 35 independent sub-libraries with a total scaleof 14 million compounds, It incorporates over 14 experimentally validated covalent warheads capable of targeting cysteine, lysine, arginine, aspartic acid and glutamic acid. This library is constructed with diverse drug like core scaffolds and integrated controllable covalent warheads, it features structural diversity, reaction spec

HY-L925

Cysteine Protease Focused Library	9,188 compounds
Cysteine proteases (CPs), a key enzyme family regulating physiological metabolism and mediating pathological processes (such as abnormal bone resorption, tumour invasion, and pathogen infection), represent a core therapeutic target for developing specific inhibitors in disease intervention. Currently reported CP inhibitors primarily achieve their inhibitory function by precisely binding to CP active pockets (e.g., S1-S4 non-primed regions or S1'-S2' primed regions) and forming covalent/non-covalent interactions with the active site cysteine residues, providing clear structural references for the development of novel inhibitors. This compound library, designed based on the core strategy of "similarity-based known active structures", contains over 200 cysteine protease inhibitors. Leveraging AI-driven molecular screening technology, it retains the critical pharmacological and shape features of reported CP inhibitors, serving as a specialized tool for efficiently discovering novel cysteine protease inhibitors.

Cysteine Protease Focused Library

9,188 compounds

Cysteine proteases (CPs), a key enzyme family regulating physiological metabolism and mediating pathological processes (such as abnormal bone resorption, tumour invasion, and pathogen infection), represent a core therapeutic target for developing specific inhibitors in disease intervention. Currently reported CP inhibitors primarily achieve their inhibitory function by precisely binding to CP active pockets (e.g., S1-S4 non-primed regions or S1'-S2' primed regions) and forming covalent/non-covalent interactions with the active site cysteine residues, providing clear structural references for the development of novel inhibitors.

This compound library, designed based on the core strategy of "similarity-based known active structures", contains over 200 cysteine protease inhibitors. Leveraging AI-driven molecular screening technology, it retains the critical pharmacological and shape features of reported CP inhibitors, serving as a specialized tool for efficiently discovering novel cysteine protease inhibitors.

Cat. No.	Product Name	Type

HY-P3152

Streptavidin 5 Publications Verification	Biochemical Assay Reagents
Streptavidin is a ~60 kDa homotetramer. Streptavidin binds four molecules of biotin with the highest affinity. The binding affinity of biotin to streptavidin is one of the highest reported for a non-covalent interaction to date, with a K_D ~0.01 pM . Streptavidin has an immunosuppressive role . This product is a Streptavidin protein recombinantly expressed in an E. coli expression system.

Streptavidin

5 Publications Verification

Biochemical Assay Reagents

Streptavidin is a ~60 kDa homotetramer. Streptavidin binds four molecules of biotin with the highest affinity. The binding affinity of biotin to streptavidin is one of the highest reported for a non-covalent interaction to date, with a K_D ~0.01 pM . Streptavidin has an immunosuppressive role .
This product is a Streptavidin protein recombinantly expressed in an E. coli expression system.

HY-W145665

Amylose	Biochemical Assay Reagents
Amylose is not a typical small-molecule ligand with a specific traditional receptor-binding target. It is a polysaccharide. In food science and biological systems, amylose can interact with proteins and free fatty acids through non-covalent forces like hydrophobic interactions and electrostatic interactions. For example, it can form a ternary complex with them, which is related to the structure and digestion of starch. It is widely studied in the fields of food science, carbohydrate metabolism, and is also relevant in research on controlling glycemic responses, as it affects starch digestion rate .

Amylose

Biochemical Assay Reagents

Amylose is not a typical small-molecule ligand with a specific traditional receptor-binding target. It is a polysaccharide. In food science and biological systems, amylose can interact with proteins and free fatty acids through non-covalent forces like hydrophobic interactions and electrostatic interactions. For example, it can form a ternary complex with them, which is related to the structure and digestion of starch. It is widely studied in the fields of food science, carbohydrate metabolism, and is also relevant in research on controlling glycemic responses, as it affects starch digestion rate .

Cat. No.	Product Name	Target	Research Area

HY-P4076

MPG peptides, Pβ	HIV DNA Alkylator/Crosslinker	Infection
MPG peptides, Pβ is an amphipathic cell-penetrating peptide. MPG peptides, Pβ consists of three components: the hydrophobic fusion sequence (GALFLGFLGAAGSTMGA) of HIV glycoprotein 41, a spacer domain (WSQP), and the nuclear localization signal (KKKRKV) of the large T antigen of Simian virus 40. MPG peptides, Pβ can form stable non-covalent complexes with nucleic acids (including DNA) through electrostatic interactions and improve their intracellular delivery. MPG peptides, Pβ can be used in studies of HIV-1-related immune responses .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W015954

(2R,3R)-Butane-2,3-diol	Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Calcium Channel Bacterial
(2R,3R)-Butane-2,3-diol is a non-covalent, reversible agonist targeting lanthanum (La ³⁺)-sensitive calcium channels in bacteria (e.g., Escherichia coli) with an EC₅₀ of approximately 25 mM. (2R,3R)-Butane-2,3-diol binds to calcium channel proteins or related complexes, induces channel opening, promotes extracellular calcium influx, and triggers intracellular calcium transients, which may regulate bacterial physiological activities such as growth, metabolism, and signal transduction. (2R,3R)-Butane-2,3-diol mediates bacterial-host cell signaling interactions and affects the metabolic balance of intestinal microorganisms, and can be used to study lactose intolerance and other related diseases .

HY-W145665

Amylose	Human Gut Microbiota Metabolites Polysaccharides Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Saccharides Source Classification	Biochemical Assay Reagents Endogenous Metabolite
Amylose is not a typical small-molecule ligand with a specific traditional receptor-binding target. It is a polysaccharide. In food science and biological systems, amylose can interact with proteins and free fatty acids through non-covalent forces like hydrophobic interactions and electrostatic interactions. For example, it can form a ternary complex with them, which is related to the structure and digestion of starch. It is widely studied in the fields of food science, carbohydrate metabolism, and is also relevant in research on controlling glycemic responses, as it affects starch digestion rate .

HY-W012817

Methylhydroquinone	Structural Classification Natural Products Microorganisms Classification of Application Fields Other Diseases Disease Research Fields Source Classification	Environmental Pollutants COX
Methylhydroquinone is an orally active COX inhibitor with IC₅₀s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions .

HY-W015954R

(2R,3R)-Butane-2,3-diol (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Calcium Channel Bacterial
(2R,3R)-Butane-2,3-diol (Standard) is the analytical standard of (2R,3R)-Butane-2,3-diol (HY-W015954). This product is intended for research and analytical applications. (2R,3R)-Butane-2,3-diol is a non-covalent, reversible agonist targeting lanthanum (La ³⁺)-sensitive calcium channels in bacteria (e.g., Escherichia coli) with an EC₅₀ of approximately 25 mM. (2R,3R)-Butane-2,3-diol binds to calcium channel proteins or related complexes, induces channel opening, promotes extracellular calcium influx, and triggers intracellular calcium transients, which may regulate bacterial physiological activities such as growth, metabolism, and signal transduction. (2R,3R)-Butane-2,3-diol mediates bacterial-host cell signaling interactions and affects the metabolic balance of intestinal microorganisms, and can be used to study lactose intolerance and other related diseases .

HY-W012817R

Methylhydroquinone (Standard)	Natural Products Microorganisms Source Classification	COX Reference Standards
Methylhydroquinone (Standard) is the analytical standard of Methylhydroquinone. This product is intended for research and analytical applications. Methylhydroquinone is an orally active COX inhibitor with IC50s of 480.7 μM and 52.2 μM for ovine COX-1 and human recombinant COX-2, respectively. Methylhydroquinone has potential DNA damaging effects: 1) inhibiting COX-1 to reduce prostaglandin synthesis and exert anti-inflammatory activity; 2) inducing DNA single-strand breaks. Methylhydroquinone exerts its effects by competitively binding to the active sites of COX-1 (such as Tyr385, Met522) and non-covalent interactions[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

non-covalent interaction

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Natural
Products